Physician profile
Jonathan Arnold Edwards
NPI 1043284458
$5,511.96
in general payments reported to CMS, 2019-2025
42 companies · $82.38 in 2025
The $82.38 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.25 · 2020: $369 · 2021: $1,619 · 2022: $973 · 2023: $1,996 · 2024: $405 · 2025: $82.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,045.64 | 2021-2024 | Austedo, Uzedy, Austedo Xr |
| Abbvie INC. | $797.27 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $516.40 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Amgen INC. | $449.31 | 2020-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $447.45 | 2021-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $206.39 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $204.77 | 2021-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $179.73 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.13 | 2021-2023 | Caplyta |
| Acadia Pharmaceuticals INC | $125.00 | 2024 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $105.61 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $101.55 | 2020-2025 | Winrevair |
| Axsome Therapeutics, INC. | $97.57 | 2023 | Auvelity |
| Corium, LLC | $92.85 | 2022-2023 | Azstarys |
| Indivior INC. | $87.82 | 2022-2023 | Perseris |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.